Braveheart Bio, Inc. (BRVE) stock

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026

$19.62−0.88 (-4.29%)

Close on Nov 13, 2026Market cap $1.77BP/E –Yield –

Braveheart Bio statistics

34 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $1.77B; $272.32M
Enterprise Value: $1.26B; $146.23M
PB Ratio: 3.55; 2.00
P/TBV Ratio: 3.55; 2.22

Share statisticsIndustry

Shares Outstanding: 90M; 58M
Shares Change (QoQ): 989.0%; 0.50%
Float: 18M; 49M
Shares Held by Insiders: 80.2%; 11.7%

Short sellingIndustry

Short Interest: 5M; –
Short Interest Change: 5.06%; -0.80%
Short % of Float: 28.9%; 9.01%
Short % of Shares Outstanding: 5.72%; 6.30%
Days to Cover: 19.63; 5.15

Stock price statisticsIndustry

20-Day Moving Average: $20.51; –
50-Day Moving Average: $22.08; –
Average True Range (14): $1.65; –
Price Change (1 Week): 5.48%; -1.15%
Price Change (1 Month): 0.36%; -4.87%
Price Change (3 Months): -29.1%; -21.0%
Average Volume (10 Days): 562,482; –
Average Volume (20 Days): 406,199; –
Average Volume (90 Days): 492,396; –
Relative Volume: 1.09; 0.70
Relative Strength Index (14): 44.8; 43.4

Financial positionIndustry

Current Ratio: 21.57; 3.30
Quick Ratio: 30.20; 2.39

Balance sheetIndustry

Cash & Short-Term Investments: $503.50M; $68.68M
Net Cash (Debt): $503.50M; $17.76M
Net Cash Per Share: $5.59; $0.80
Equity (Book Value): $497.60M; $53.89M
Book Value Per Share: $5.53; $1.50
Tangible Book Value: $497.60M; $27.13M
Working Capital: $342.90M; $79.99M

Scores and fair valueIndustry

Altman Z-Score: 63.38; 0.23

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	BRVE	S&P 500	Difference	BRVE per year	S&P 500 per year
1 month	+1.5%	-3.0%	+4.5 pts
3 months	-24.5%	-2.8%	−21.7 pts

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

5M BRVE shares were sold short on Oct 30, 2026, up 5.1% from the previous report, or 28.92% of the shares available to trade. At recent volumes it would take 19.6 days to buy them back. Over the last 20 sessions, 82.3% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	5,153,595	+5.1%	262,573	19.6
Oct 15, 2026	4,905,289	+18.8%	417,079	11.8
Sep 30, 2026	4,128,974	+67.8%	809,950	5.1
Sep 15, 2026	2,461,086	+76.1%	328,415	7.5
Aug 31, 2026	1,397,189	+64.8%	249,992	5.6
Aug 14, 2026	847,773	–	650,680	1.3

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?